Sales For 27 JPMA Member Companies Increase By 3.8 Percent In FY2007
This article was originally published in PharmAsia News
The Japan Pharmaceutical Manufacturers Association summarized results of 27 Tokyo Stock Exchange publicly traded member companies for fiscal year 2007. Total sales increased 3.8 percent to ¥6.82 trillion. Sales in the overseas market, increasing by 9.1 percent compared to the 1.3 percent increase in the Japanese domestic market, drove the growth. Compared to sales, income increased by a mere 2.5 percent to ¥1.371 trillion. M&A activities, licensing payments and especially R&D expenses, which increased by 16.5 percent to ¥1.1989 trillion, all resulted in a lower income. JPMA estimates a further increase in revenue due to more expansions in overseas markets for some major drugs, and a double digit decrease in income due to continuous R&D expenses. . (Click here for more - Japanese language
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.